158 related articles for article (PubMed ID: 19706063)
1. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy.
Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC
Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063
[No Abstract] [Full Text] [Related]
2. [Rimonabant (Acomplia)].
Duh D; Vanddevijver A
J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
[No Abstract] [Full Text] [Related]
3. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687
[No Abstract] [Full Text] [Related]
4. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
Kintscher U
Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
[No Abstract] [Full Text] [Related]
5. [Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].
MMW Fortschr Med; 2007 Jun; 149(27-28):8. PubMed ID: 17717874
[No Abstract] [Full Text] [Related]
6. [Rimonabant. Risk of depression has not been finally clarified].
Kreutzkamp B
Med Monatsschr Pharm; 2008 May; 31(5):191-2. PubMed ID: 18552079
[No Abstract] [Full Text] [Related]
7. [Sleep disorders associated with treatment with rimonabant].
Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M
Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208
[No Abstract] [Full Text] [Related]
8. [Prescription of rimonabant in the early stage of pregnancy?].
Picksak G; Stichtenoth DO
Med Monatsschr Pharm; 2008 Mar; 31(3):107-8. PubMed ID: 18429532
[TBL] [Abstract][Full Text] [Related]
9. [Selective cannabinoid receptor antagonists].
Kreutz S; Korf HW; Schubert-Zsilavecz M
Pharm Unserer Zeit; 2006; 35(6):512-20. PubMed ID: 17137082
[No Abstract] [Full Text] [Related]
10. Rimonabant, obesity and diabetes.
Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
[TBL] [Abstract][Full Text] [Related]
11. [Endocannabinoid and endocannabinoid receptor antagonists].
Heinzl S
Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
[No Abstract] [Full Text] [Related]
12. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
Gadde KM; Allison DB
Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of the weight-loss drug rimonabant.
Blüher M
Lancet; 2008 Feb; 371(9612):555-6; author reply 556-7. PubMed ID: 18280321
[No Abstract] [Full Text] [Related]
14. Impairments in endocannabinoid signaling and depressive illness.
Hill MN; Gorzalka BB
JAMA; 2009 Mar; 301(11):1165-6. PubMed ID: 19293417
[No Abstract] [Full Text] [Related]
15. Depression and weight loss: opposite outcome for surgery and rimonabant?
Chaput JP; Tremblay A
Obes Rev; 2008 Sep; 9(5):504-7. PubMed ID: 18643944
[No Abstract] [Full Text] [Related]
16. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
[No Abstract] [Full Text] [Related]
17. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
[No Abstract] [Full Text] [Related]
18. End of the line for cannabinoid receptor 1 as an anti-obesity target?
Jones D
Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439
[TBL] [Abstract][Full Text] [Related]
19. [The endocannabinoid system and treatment of obesity].
Aronsen L
Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
[TBL] [Abstract][Full Text] [Related]
20. [2008: the end of rimonabant's story].
Paris M
Ann Pharm Fr; 2009 May; 67(3):167-8. PubMed ID: 19446664
[No Abstract] [Full Text] [Related]
[Next] [New Search]
